This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ALDH1A3 / Retinaldehyde dehydrogenase 3 · IHC design guide
Design Immunohistochemistry for ALDH1A3
Plan ALDH1A3 IHC-P around cytoplasmic staining in prostate glandular cells (HPA tissue IHC). Start with the catalog antibody’s 2–5 μg/mL IHC range (datasheet A03030) and interpret staining in light of presumed off-target binding (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ALDH1A3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasm in prostate glandular cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A03030) | |
| Positive control | Prostate+4 more · see all | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Presumed off-target staining may confound interpretation (HPA tissue IHC) | |
| Regulation | Tissue-enhanced RNA in prostate and bladder (HPA RNA) | |
| Isoform / epitope | No annotated isoforms; mature chain spans residues 2–512 (UniProt) |
Section 1
Recommended ALDH1A3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published ALDH1A3 protocols for bladder tissue (PMC12215419) and paraffin tissue sections (PMC6769487).
| Sample | Paraffin-embedded human prostate cancer tissue; fixative not specified (datasheet A03030) |
| Fixation | Image fixative and duration unreported (datasheet A03030); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A03030); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A03030) |
| Primary antibody | Rabbit anti-ALDH1A3, 2-5μg/ml (datasheet A03030) |
| Primary incubation | Overnight at 4 °C (datasheet A03030) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A03030) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ALDH1A3-positive staining in glandular cells of prostate (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in several different tissue types including prostate. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet A03030). If needed, compare the published pH 9 retrieval conditions (PMC12215419; PMC6769487).
Section 2
What Is the Expected ALDH1A3 Staining Pattern?
In paraffin section IHC, expect predominantly cytoplasmic ALDH1A3 staining, with high staining in prostate glandular cells and testis peritubular cells (HPA: tissue IHC; UniProt P47895: cytoplasm). ALDH1A3 has no transmembrane segment (UniProt P47895: topology). HPA rates its tissue IHC evidence Enhanced, while reporting medium agreement with RNA data and presumed off target staining that was disregarded (HPA: reliability).
| Distinct cytoplasmic staining in prostate glandular cells or testis peritubular cells, with interpretable tissue structure. | This matches the reported high tissue IHC pattern and UniProt cytoplasmic localization (HPA: prostate and testis tissue IHC; UniProt P47895: cytoplasm). Compare the stained cells with neighboring cells on the same section; tissue identity alone does not establish that the signal is specific (standard IHC practice). |
| Predominantly nuclear staining on a chromogenic paraffin section, with little convincing cytoplasmic signal. | Treat this as an IHC pattern requiring verification against controls: UniProt lists cytoplasm, and HPA describes tissue IHC as cytoplasmic (UniProt P47895: subcellular location; HPA: tissue IHC profile). HPA separately reports supported nucleoplasmic staining in ICC-IF, so a nuclear IF image cannot by itself validate nuclear IHC staining (HPA: subcellular ICC-IF). |
| Strong staining in a cell population HPA lists as not detected, or staining that ignores expected cell boundaries. | Investigate antibody cross-reactivity or detection-system activity before calling it ALDH1A3 (HPA: tissue IHC negative examples; standard IHC practice). HPA reports presumed off target binding in its tissue assessment, so its Enhanced rating is not a guarantee that every stained cell is positive (HPA: reliability). |
| Uniform brown haze across stroma, empty spaces, and cells, with no readable cytoplasmic pattern. | A diffuse signal cannot establish cell-specific expression (standard IHC practice). Check a no-primary control and inspect whether chromogen deposition, incomplete blocking, or detection-system background follows tissue compartments; use the control result to identify the source before changing the biological interpretation (standard IHC practice). |
| No signal in adequately preserved prostate glandular cells or testis peritubular cells. | A run-level sensitivity or reagent problem is plausible because HPA reports high staining in those cell populations (HPA: tissue IHC). Review antibody identity, section handling, retrieval conditions, dilution, detection reagents, and control performance as general IHC checks; the supplied sources give no ALDH1A3-specific retrieval or fixation effect (standard IHC practice). |
💡Expected ALDH1A3 appearanceCall a paraffin section positive when cell-defined cytoplasmic staining is clear in prostate glandular cells or testis peritubular cells at the HPA-reported high level; isolated nuclear staining or uniform brown haze warrants control-based review (HPA: tissue IHC; UniProt P47895: cytoplasm; standard IHC practice).
| Cell population used as a reference | HPA reports high staining in prostate glandular and testis peritubular cells, and medium staining in bronchial respiratory epithelium, endometrial stromal cells, gallbladder and stomach glandular cells, and bladder urothelial cells (HPA: tissue IHC). Judge a section by its reported cell population, not by a whole-tissue label (standard IHC practice). |
| Negative and low-staining comparators | HPA lists adrenal glandular cells, heart cardiomyocytes, and lymph-node germinal-center cells as not detected; it lists lung alveolar cells and thyroid glandular cells as low (HPA: tissue IHC). A negative comparator can reveal nonspecific staining, but a low-staining sample is a weak sensitivity check (standard IHC practice). |
| Strength and limits of IHC evidence | The HPA046271 antibody has Enhanced IHC validation, whereas the supplied HPA record gives no IHC status for HPA064749 (HPA: antibody validation). HPA also reports medium agreement between staining and RNA data and disregarded presumed off target binding; interpret unexpected patterns with controls (HPA: reliability; standard IHC practice). |
| Protein localization and processing | UniProt places ALDH1A3 in the cytoplasm, reports no transmembrane segment or signal peptide, and lists a 2–512 chain with no annotated isoforms (UniProt P47895: subcellular location, topology, processing, isoforms). These annotations support a cellular cytoplasmic expectation but do not identify the antibody epitope or establish antigen-retrieval requirements (UniProt P47895; standard IHC practice). |
| IF/ICC: What pattern should be expected? | HPA reports supported nucleoplasmic localization with additional cytosolic signal in ICC-IF images from A-431, U-251MG, U2OS, and PC-3 cells (HPA: subcellular ICC-IF). This assay-specific observation differs from the cytoplasmic tissue IHC profile; evaluate IF/ICC localization on its own guide page (HPA: tissue IHC and subcellular ICC-IF). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are blank. | The run may lack sufficient signal, or the intended positive cell population may be absent from the examined area (HPA: tissue IHC; standard IHC practice). | Locate prostate glandular cells or testis peritubular cells in the section; then check antibody identity, dilution, retrieval setup, detector, and a concurrent positive control (HPA: tissue IHC; standard IHC practice). No target-specific retrieval condition is supplied. |
| Nuclei dominate the IHC signal. | The paraffin section pattern conflicts with HPA cytoplasmic tissue IHC and UniProt cytoplasmic localization; the cause cannot be assigned from appearance alone (HPA: tissue IHC; UniProt P47895: cytoplasm). | Compare a no-primary control and an expected positive tissue, and check whether staining remains in the reported cytoplasmic cell population (HPA: tissue IHC; standard IHC practice). |
| Cells expected to be negative stain strongly. | Cross-reactivity or detection background is possible; HPA's tissue review explicitly notes presumed off target binding (HPA: reliability; standard IHC practice). | Check the cell identity and compare the same run with a no-primary control and HPA-listed negative cell populations before scoring those cells as ALDH1A3-positive (HPA: tissue IHC; standard IHC practice). |
| Brown staining is widespread and poorly cell-defined. | Nonspecific reagent binding or endogenous chromogenic detection activity may contribute, depending on the detection chemistry used (standard IHC practice). | Review blocking and wash steps, inspect a no-primary control, and address endogenous activity appropriate to the chosen detection system; reassess only cell-defined signal afterward (standard IHC practice). |
| Only faint signal appears in a low-staining tissue. | HPA already reports low staining in some populations, including lung alveolar cells and thyroid glandular cells (HPA: tissue IHC). | Check a concurrently stained HPA high positive cell population before changing assay conditions; score weak tissue signal only when its cellular location and controls are interpretable (HPA: tissue IHC; standard IHC practice). |
| A retrieval change gives an unexpected result. | The supplied HPA and UniProt records do not establish ALDH1A3-specific retrieval or fixation sensitivity (HPA: supplied tissue IHC record; UniProt P47895). | Compare retrieval conditions using the same positive and negative controls, keeping detection and scoring consistent; treat any improvement as an assay observation, not a documented ALDH1A3 property (standard IHC practice). |
Experiment evidence
IHC & IF images showing ALDH1A3 staining
A03030 · IHCIHC analysis of ALDH1A3 using anti-ALDH1A3 antibody (A03030). ALDH1A3 was detected in a paraffin-embedded section of human prostate cancer t
A03030 · IHCIHC analysis of ALDH1A3 using anti-ALDH1A3 antibody (A03030). ALDH1A3 was detected in a paraffin-embedded section of human prostate cancer t
A03030 · IFIF analysis of ALDH1A3 using anti-ALDH1A3 antibody (A03030). ALDH1A3 was detected in an immunocytochemical section of SiHa cells. Enzyme ant
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000184254-ALDH1A3/tissue/cerebral+cortex#imid_12820119
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000184254-ALDH1A3/tissue/colon#imid_12820045
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000184254-ALDH1A3/tissue/liver#imid_12820046
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000184254-ALDH1A3/tissue/kidney#imid_12820039
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA046271; green = ALDH1A3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA046271; green = ALDH1A3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ALDH1A3 IHC & IF
🧪Run prostate first: glandular cells should stain (HPA: High in prostate glandular cells). Use adrenal gland as the negative tissue (HPA: Not detected in adrenal gland glandular cells); cells without specific staining on the prostate slide should retain intact morphology and show only background signal.
Positive control tissue: Prostate (Glandular cells, HPA High)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ALDH1A3 in A-431, U-251MG, U2OS, PC-3, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and concentration-matched rabbit IgG controls, matching clonality where applicable (selected A03030 caption: rabbit primary antibody; standard IHC practice). Confirm specificity with ALDH1A3 knockout material or immunizing-peptide competition if available, and block endogenous peroxidase on prostate sections before HRP/DAB detection (selected A03030 caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A03030 paraffin-section caption does not state the fixative (selected A03030 caption). That caption uses heat retrieval in EDTA pH 8.0, but retrieval dependence has not been established (selected A03030 caption). Whether frozen sections or IF are easier is unreported; assess IF localisation against the reported nucleoplasmic and cytosolic pattern (HPA: supported subcellular locations).
HPA tissue IHC evidence for ALDH1A3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Presumed off target binding observed and disregarded.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Prostate | Glandular cells | High | Protein (IHC) | HPA → |
| Testis | Peritubular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Medium | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ALDH1A3 IHC Tips
Use the documented paraffin-section workflow as the starting point, then judge staining by cell type, compartment, and controls.
Which retrieval conditions should I use when ALDH1A3 staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A03030). The documented prostate cancer section then received 2 μg/ml primary antibody overnight at 4°C, so compare retrieval changes against that starting concentration and incubation (datasheet A03030). If staining remains weak, compare a second retrieval condition on adjacent sections while keeping detection and imaging consistent; excessive heating can damage morphology and complicate scoring (standard IHC practice). Include a documented positive compartment, such as prostate glandular cells, and a no-primary control in each run (HPA: high in prostate glandular cells; standard IHC practice). Judge improvement by clearer cellular staining without a parallel rise in background (standard IHC practice).
Could fixation explain inconsistent ALDH1A3 staining across paraffin blocks?
The A03030 tissue caption identifies a paraffin section but does not report its fixative, and target-specific fixation sensitivity is unknown (datasheet A03030). Record the fixative and fixation interval for each block before comparing staining across cases; processing differences can change epitope accessibility and morphology (standard IHC practice). Run sections from the same block together with the documented EDTA pH 8.0 retrieval and 2 μg/ml primary concentration to reduce workflow variation (datasheet A03030; standard IHC practice). If only some blocks stain, examine internal cell-type controls and tissue preservation before assigning a biological difference (standard IHC practice). Do not infer a fixation effect from expression patterns or protein topology alone (HPA tissue IHC; UniProt P47895 topology).
How should I assess cytoplasmic and nuclear ALDH1A3 staining in IHC?
Expect cytoplasmic staining as the main tissue-IHC reference pattern: ALDH1A3 is annotated in the cytoplasm, and tissue IHC describes cytoplasmic expression across several tissues (UniProt P47895 subcellular location; HPA tissue IHC). HPA cell-imaging data also support nucleoplasm as a main location and cytosol as an additional location, so nuclear signal warrants evaluation rather than automatic rejection (HPA subcellular). Compare nuclear and cytoplasmic staining separately within the same cell type and across adjacent sections, using identical retrieval and detection conditions (standard IHC practice). A diffuse nuclear haze that also appears in a no-primary control supports a staining artefact (standard IHC practice). Resolve persistent disagreement with an independently validated antibody or orthogonal expression evidence (standard IHC practice).
Could an isoform or hidden epitope explain variable staining?
The supplied record annotates 0 isoforms and no transmembrane segment; it does not establish which epitope A03030 recognizes (UniProt P47895 isoforms and topology; datasheet A03030). ALDH1A3 is listed as a 512-residue protein with an N-terminal acetylation annotation, but those facts alone cannot predict antibody accessibility after processing (UniProt P47895 length and modified residues). When a suspected epitope problem arises, check the antibody's stated immunogen or mapped epitope before drawing a molecular explanation (standard IHC practice). Compare adjacent sections using the documented EDTA pH 8.0 retrieval and consistent detection, then assess whether specific cellular staining improves (datasheet A03030; standard IHC practice). Treat an absent signal as inconclusive until positive tissue and assay controls work (standard IHC practice).
How can I use IF to investigate an ambiguous IHC pattern?
For secondary IF/ICC follow-up, image ALDH1A3 alongside a validated marker of the cell population being assessed, such as prostate glandular cells in a prostate sample (HPA: high in prostate glandular cells; standard IF practice). Choose a fluorophore channel with low signal from that specimen's autofluorescence, and inspect an unstained or no-primary control before interpreting overlap (standard IF practice). Because ALDH1A3 has no transmembrane segment and is annotated in the cytoplasm, permeabilise sufficiently for intracellular antibody access while preserving cellular boundaries (UniProt P47895 topology and subcellular location; standard IF practice). Compare nuclear and cytosolic signal separately: HPA cell imaging supports both locations, whereas tissue IHC reports cytoplasmic expression (HPA subcellular; HPA tissue IHC). IF conditions require their own validation rather than assuming the paraffin-section conditions transfer (standard IF practice).
What should I check when DAB staining obscures ALDH1A3-positive cells?
The documented A03030 section used 10% goat-serum blocking, 2 μg/ml primary antibody overnight at 4°C, and peroxidase detection with DAB (datasheet A03030). Check a no-primary section for secondary-reagent or tissue background, and include a peroxidase block as a general chromogenic IHC step (standard IHC practice). If background persists, compare shorter DAB development or a lower primary concentration while retaining a positive tissue control; those are optimisation trials, not documented ALDH1A3 conditions (standard IHC practice). Inspect damaged edges, folds, and necrotic areas separately from intact cells because these regions can collect nonspecific signal (standard IHC practice). HPA reports presumed off-target staining, so require convincing cell-type and compartment agreement before calling weak staining positive (HPA tissue IHC reliability).
How should I score heterogeneous ALDH1A3 staining in paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population before measurement; prostate glandular cells provide a documented high-expression reference, while urinary-bladder urothelial cells have medium staining in the supplied tissue profile (HPA tissue IHC). For DAB sections, record the percentage of positive target cells and an intensity-based H-score, keeping cytoplasmic and nuclear scores separate when both appear (standard IHC practice; HPA subcellular). Normalise positive-cell counts to all evaluable cells of the same type, or report positive-cell density per mm² of evaluable tissue area (standard IHC practice). Exclude folds, necrosis, and section edges by a prespecified rule, then apply the same threshold and illumination settings across slides (standard IHC practice). Report control performance and the scored compartment alongside each result (standard IHC practice).
When should I doubt an apparent ALDH1A3-positive IHC result?
Prioritise intact cells with a reproducible cytoplasmic pattern, consistent with the protein annotation and tissue-IHC profile (UniProt P47895 subcellular location; HPA tissue IHC). Compare the stained cell type with references: prostate glandular cells are high, whereas adrenal glandular cells and lymph-node germinal-center cells were not detected in the supplied profile (HPA tissue IHC). Strong signal restricted to an unexpected cell type, a damaged edge, or necrosis calls for repeat staining and control review (standard IHC practice). Nuclear staining needs separate assessment because HPA cell imaging supports nucleoplasmic ALDH1A3 despite the cytoplasmic tissue-IHC profile (HPA subcellular; HPA tissue IHC). Check no-primary and peroxidase-block controls before attributing DAB deposits to ALDH1A3; presumed off-target staining was reported in the HPA assessment (standard IHC practice; HPA tissue IHC reliability).
Boster reagents
Best ALDH1A3 / Retinaldehyde dehydrogenase 3 IHC Antibodies
A03030 has IHC data from paraffin sections of human prostate cancer and rat lung (IHC image captions), plus IF/ICC data from SiHa cells (IF image caption).
Real IHC data
Anti-ALDH1A3 Antibody ®
Cat # A03030
A03030 will render with IHC evidence from paraffin sections of human prostate cancer and rat lung (IHC image captions). It also has IF/ICC evidence from SiHa cells (IF image caption) and lists human, mouse, and rat reactivity (catalog reactivity).
Which to pick: For tissue IHC, choose A03030: its images document paraffin sections with EDTA retrieval at pH 8.0 and 2 μg/mL primary antibody; the fixative is unreported (A03030 IHC image captions). For IF/ICC, choose A03030: its SiHa-cell IF image uses 5 μg/mL, and the catalog lists both applications (A03030 IF image caption; catalog applications). For cross-species work, A03030 lists human, mouse, and rat reactivity (catalog reactivity), with IHC images for human and rat (A03030 IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P47895 (AL1A3_HUMAN, Retinaldehyde dehydrogenase 3).
- Human Protein Atlas. ALDH1A3 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. ALDH1A3 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. ALDH1A3 antibody validation summary (2 antibodies).
- Expression of ALDH1 isotypes and its potential as a prognostic and diagnostic marker in patients with muscle invasive bladder cancer. Scientific reports 2025 — PMC12215419.
- Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic β cells in diabetic mice. Nature communications 2016 — PMC5013715.
- MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer. PloS one 2015 — PMC4430273.
- Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells. Cancers 2019 — PMC6769487.
- PubMed PMID:7698756 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:21269460 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ALDH1A3 (Retinaldehyde dehydrogenase 3). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A03030). Validated IHC antibody: A03030 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Prostate (Glandular cells); negative Adrenal gland. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human prostate cancer tissue; fixative not specified (datasheet A03030); 2. Fixation: Image fixative and duration unreported (datasheet A03030); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A03030); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A03030); 8. Primary antibody: Rabbit anti-ALDH1A3, 2-5μg/ml (datasheet A03030); 9. Primary incubation: Overnight at 4 °C (datasheet A03030). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Presumed off-target staining may confound interpretation (HPA tissue IHC); Isoform / epitope: No annotated isoforms; mature chain spans residues 2–512 (UniProt); Regulation: Tissue-enhanced RNA in prostate and bladder (HPA RNA). Evidence: UniProt P47895, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A03030, PMC12215419, PMC6769487. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ALDH1A3/immunohistochemistry-ihc-guide.